Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC1101 in advanced solid tumors with KRAS G12D mutation
NCT06403735Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLC1101 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more, sponsored by Qilu Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 25 days, Maximum Tolerated Dose at 1 year and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
QLC1101
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06403735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06403735.